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Fungi cause more than a billion skin infections, more than 100 million
mucosal infections, 10 million serious allergies and more than a million
deaths each year. Global mortality owing to fungal infections is greater
than for malaria and breast cancer and is equivalent to that owing to tuber-
culosis (TB) and HIV. These statistics evidence fungal infections as a major
threat to human health and a major burden to healthcare budgets world-
wide. Those patients who are at greatest risk of life-threatening fungal
infections include those who have weakened immunity or have suffered
trauma or other predisposing infections such as HIV. To address these
global threats to human health, more research is urgently needed to under-
stand the immunopathology of fungal disease and human disease
susceptibility in order to augment the advances being made in fungal diag-
nostics and drug development. Here, we highlight some recent advances in
basic research in medical mycology and fungal immunology that are begin-
ning to inform clinical decisions and options for personalized medicine,
vaccine development and adjunct immunotherapies.
This article is part of the themed issue ‘Tackling emerging fungal threats
to animal health, food security and ecosystem resilience’.1. Introduction
Fungi represent a major threat to human health accounting collectively for more
than a billion skin infections, more than 100 million mucosal infections,
10 million serious allergies and more than a million deaths each year. Global
mortality owing to fungal infections is greater than for malaria and breast
cancer and is equivalent to that for tuberculosis (TB) and HIV [1]. Fungal infec-
tions induce a complex set of disease states in which pathology can be the result
of fungal virulence factors that cause tissue destruction or, alternatively, can
result from inflammation caused by the presence of the fungus [2]. Conse-
quently, it is important to understand the immunopathology of fungal
infections in order to be able to consider the opportunities for augmentative
immunomodulatory treatments. Few fungi are primary pathogens of healthy
humans and most life-threatening fungal infections occur in the immuno-
compromised patients with trauma, HIV infection, immunosuppression and
neutropenia and where the normally protective bacterial microflora is disrupted
[1]. To understand the balance between immune surveillance, disease pro-
gression, host invasion and pathology, it is therefore important to be able to
define the nature of the protective immune response to fungal invaders and
other factors that predispose us to infection.
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Figure 1. Immune recognition of fungi and their cell walls. (a–e) The cell wall structure of a range of fungal pathogens. The conserved inner wall (grey) is
composed mainly of b-1,3-glucan and chitin (lacking in the Pneumocystis wall). The outer wall is predominantly of mannan (Candida, pink); hydrophobins, melanin
and a-glucan (Aspergillus conidium, dark blue) and galactomannan and galactosaminoglycan (Aspergillus hypha, green); capsular glucuronoxylomannan, galactox-
ylomannan (Cryptococcus, light blue) or a-glucan (Histoplasma and Blastomyces, yellow). PAMP–PRR interactions for fungal cell recognition are shown above.
Organism names are as in the text, S. apiospermum ¼ Scedosporium apiospermum. The figure was provided by Dr Jeanette Wagener.
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
371:20150462
2
 on October 24, 2016http://rstb.royalsocietypublishing.org/Downloaded from 2. Induction and suppression of
immunopathology
More than a decade of fungal immunology research has
focused on defining the molecular interactions between
pathogen associated molecular patterns (PAMPs), which are
dominated by component polysaccharides of the fungal cell
wall, and their cognate pattern recognition receptors (PRRs)
from the toll-like receptor (TLR), C-type lectin (CTL) and
nod-like receptor (NLR) families [3–5] (figure 1). Recognition
events lead to engulfment of fungal cells, cell signalling, the
release of cytokines and other molecules that recruit phago-
cytes and antigen-presenting cells to the sites of infection,
leading to the activation of naive T cells and the induction
of antibody production by B cells. Macrophages and neutro-
phils provide first-line defences killing fungal invaders by
attacking fungal cells with variety of enzymes and toxic oxi-
dative and nitrosative compounds. Dendritic cells direct the
maturation of naive CD4þ T helper cells (TH) and regulatory
T cell (TReg) populations, leading to both protective and
sometimes pathological inflammatory reactions to the pres-
ence of a fungus [2]. An important dynamic in fungal
immunology is that the pathology caused by a fungal invader
can be mediated either by the destructive forces imparted by
virulence factors or by the over-activation of the inflamma-
tory response causing collateral damage to host tissue. Therecently described candidalysin product of a peptide derived
from proteolysis of the Eec1 protein is an example of a fungal
virulence attribute that inflicts damage on the host [6]. The
polysaccharide b-1,3 glucan, a signature molecule in the cell
walls of all fungal pathogens, is a strong activator of inflam-
mation via activation of TH17 immune responses and of the
NLRP3 inflammasome. These responses are required for
immune protection, but can also lead to pathological tissue
damage if not subject to attenuation and immunomodulatory
regulation [7].
Recent work exemplifies the principle that understanding
the nature of the recognition mechanism and immune
response can present novel therapeutic options. For example,
Brown and co-workers showed that the normal immune
response to Fonsecaea pedrosoi was inadequate to generate a
protective inflammatory response [8]. This fungus is an
agent of chromoblastomycosis—a chronic skin infection that
is normally highly recalcitrant to treatment with antifungal
antibiotics and often requires surgical debridement to effect
adequate treatment (figure 2). In a pre-clinical mouse
model of F. pedrosoi infection, it was shown that intravenous
or intraperitoneal injection of bacterial lipopolysaccharide
(LPS) augmented the primary recognition of the fungus
mediated by the mincle CTL, leading to complete elimination
of the fungus [8]. A recent clinical trial has shown that topical
administration of the TLR7 agonist Imiquimod, with and
Figure 2. Treatment of chromoblastomycosis from time 0 to 20 months’ application of topical imiquimod 5% plus itraconazole 200 mg day21 [9]. With thanks to
Paulo R. Criado and Walter B. Ju´nior and G. de Sousa.
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moting the elimination of F. pedrosoi from skin lesions [9]. It is
therefore important to understand the virulence properties
and immune recognition of the major fungal pathogens in
order to inform augmentative immunotherapy options. At
present, our understanding of these areas is dominated by
investigations of model pathogens such as Candida albicans,
and we are not yet able extrapolate this knowledge to be
predict how even related Candida species induce pathology.
Studies of fungal immune recognition emphasize the
importance of several classes of cell wall polysaccharides
[3–5]. The outer walls of fungi are chemically diverse and
contain a variety of polymers that are either mildly proinflam-
matory or more or less immunologically inert, providing a
mask over the inner cell wall that is normally dominated by
the highly proinflammatory b-1,3-glucan layer that is recog-
nized by dectin-1 [10]. Damage to the outer mannan layer of
the Candida cell wall unmasks b-1,3-glucan, which also occurs
naturally when the cell wall is attacked by the lytic enzymes
of phagocytes or exposure to antifungal drugs such as echino-
candins that damage b-1,3-glucan and hence compromise cell
wall integrity [11]. A range of mannosylation defective mutants
of C. albicans, including och1, pmr1 andmnn1, have been shown
to have increased exposure and immune recognition of com-
ponents of the inner cell wall [12,13]. Fungal mannans are
mildly proinflammatory and are the natural ligands for a
wide range of PRRs, including TRL2, TLR4, mannose receptor,
mincle, dectin-2, DC-SIGN and galectin 3 [4] (figure 1).
However, fungal b-1,3-glucan is the most immunologically
active fungal PAMP, and the full immune response to a
fungus does not occur until b-1,3-glucan in the inner cell wall
is exposed. Cooperative, simultaneous recognition of multi-
ple cell wall components via receptor complexes results in
amplification of the recognition response [14].
A second signature polysaccharide of the inner fungal cell
wall is chitin. This is present in variable quantities in differentfungi and can be more or less deacetylated to chitosan. Chitin
of C. albicans and other fungi and invertebrates induced
particle size-dependent immune responses from myeloid
cells. Larger particles induced TNF, IL-6 and other proinflam-
matory cytokines, whereas smaller-sized particles induced
the anti-inflammatory cytokine IL-10 via a novel receptor sig-
nalling pathway involving the mannose receptor, NOD2 and
TLR9 [15]. Fungal chitin also induced eosinophilia that may
be linked to asthma with fungal sensitization. Administration
of highly purified fungal chitin into the peritoneum of mice
inhibited the recruitment of inflammatory cells associated
with co-administration of LPS [15]. Chitin particles also have
been shown to induce IL-10 in the colonandoffset thepathology
associated with inflammatory gut disorders [16]. Moreover,
echinocandin-treated cells ofCandida andAspergillusupregulate
chitin production in theirwalls to offset damage inflicted on cell
wall b-1,3-glucan [17,18]. Such chitin-rich cells may be less
inflammatory in vivo, thus limiting the immune response
required for their elimination by the immune system [17].
Therefore, the therapeutic administration of Imiquimod
and chitin provides contrasting examples where specific path-
ologies associated with different disease types can be treated
by either enhancing or suppressing inflammation.3. Genetic susceptibility—the impact of
genomics on medical mycology
Not all patients in high-risk groups (see above) develop invasive
disease, and these risk factors do not fully explain the sus-
ceptibility to candidiasis. Thus, the genetic make-up of the
host has also been suggested to play an important role in the
susceptibility to infection. In rare cases, single-gene defects
in patients leading to primary immunodeficiencies result
in significantly enhanced susceptibility to fungal infections.
Despite the rarity of such cases, much has been learned about
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Several immunodeficiencies are characterized by a strongly
increased susceptibility to fungal infections, among which
chronic mucocutaneous candidiasis (CMC), hyper-IgE syn-
drome (HIES) and chronic granulomatous disease (CGD) are
important examples. CMC is a heterogeneous group of clinical
syndromes characterized by chronic or recurrent infections of
the skin, nails and mucous membranes caused by Candida
spp., but also by other fungi. Recently, mutations responsible
for the impaired immune response have been identified
in several of the primary immunodeficiencies associated
with CMC. Autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED) is an autosomal recessive
disorder caused by mutations in the autoimmune regulator
(AIRE) gene and that is characterized by CMC, hypo-
parathyroidism and Addison’s disease [19,20]. It is believed
that in patients with APECED, T-lymphocyte immunological
surveillance fails owing to neutralizing autoantibodies against
IFNg and IL-17, leading to chronic Candida infection [21,22].
Autosomal-dominant chronic mucocutaneous candidiasis
(AD-CMC) is another CMC syndrome in which mutations in
the coiled-coil domain of signal transducer and activator of
transcription 1 (STAT1) have been identified as the underlying
cause [23,24]. Functional studies in these patients showed
defective T-lymphocyte immune responses, such as decreased
production of IFNg, IL-17 and IL-22, important components of
antifungal host defence [23]. In addition, defects in IL-17F or
IL-17R have also been reported as a rare cause of CMC [25].
HIES is an autosomal-dominant immunodeficiency charac-
terized by high serum IgE, eczema, recurrent Staphylococcal
skin abscesses, bone and connective tissue abnormalities and
recurrent skin and pulmonary infections, especially with
Staphylococcus aureus and Candida species [26]. There are mul-
tiple genetic causes of HIES, with mutations in STAT3 being
the most common [27,28]. In addition, defects in the dedicator
of cytokinesis 8 (DOCK8) [29] and Tyk2 [30] have also been
suggested to cause HIES. STAT3 is involved in the signal trans-
duction pathway required for the expression of many cytokine
receptors, and patients bearing STAT3 mutations have almost
no TH17 lymphocytes and fail to produce IL-17 [16–18].
Based on in vitro murine and human studies that showed
that IFNg inhibits IgE production, recombinant IFNg has
been administered to patients with HIES, resulting in
improved immunological responses [31–33]. These obser-
vations warrant future trials to evaluate the clinical response
of HIES patients to recombinant IFNg supplementation.
CGD is another condition characterized by marked
increased susceptibility to invasive bacterial and fungal
infections. The fungal infections are mainly represented by
Aspergillus,with the interestingobservationof ahighproportion
owing to A. nidulans rather than to A. fumigatus that normally
accounts for the great majority of Aspergillus-associated
human infections [28]. CGD is caused by mutations in one of
the proteins of the nicotinamide adenine dinucleotide phos-
phate oxidase complex. Mutations in all five subunits of this
complex have been described (gp91phox, p47phox, p22phox,
p67phox and p40phox), which result in the loss of function of
the complex and defective production of reactive oxygenspecies. Up to 70% of cases are X-linked, with the remaining
being autosomal [34,35]. Management of CGD typically
includes lifelong antifungal prophylaxis [36], while patients
can also benefit from administration of recombinant IFNg
especially in a prophylactic setting [37]. In addition, hemato-
poietic stem cell transplantation may offer a longer-term
solution for CGD patients [38], whereas gene therapy using ret-
roviral vectors has also been proposed as a future intervention
[39]. More research is required to evaluate the long-term safety
and effectiveness of gene therapy.
In addition to these classical immunodeficiencies, new
studies have described novel forms of immunodeficiency
based on defects in specific receptors or their associated intra-
cellular pathways. Among these, one of the most severe is the
defect in CARD9—the adaptor molecule crucial for inducing
the intracellular signalling of C-type lectin receptors. Defects
in CARD9 are associated with significantly increased suscep-
tibility to invasive fungal infections, which is mediated
through multiple immunological defects [40,41]. Complete
functional defects in one of the important C-type lectin recep-
tors, dectin-1, have also been described to be associated with
mucosal Candida infections [42,43], but the relatively common
prevalence of this mutation and the mild clinical presentation
suggest this should be regarded as a mutation associated
with an increased susceptibility risk, rather than as a classical
primary immunodeficiency.5. Common genetic variation and susceptibility
to fungal infections
In addition to primary immunodeficiencies, common var-
iants in (especially) genes coding for proteins involved in
the immune system have also been shown to govern rela-
tive susceptibility to infection (table 1). These mutations are
most often loss-of-function recessive polymorphisms. Several
epidemiological investigations have assessed the role of
TLR polymorphisms for the susceptibility to disseminated
candidiasis. The Asp299Gly TLR4 polymorphism has been
proposed to act as a susceptibility trait for systemic candidia-
sis [56] and the Asp753Gln TLR2 polymorphism resulted in
an altered cytokine profile in patients with Candida sepsis
[57]. However, the hypothesis that these polymorphisms
are involved in susceptibility to candidemia could not be
confirmed in a much larger cohort of individuals, including
patients and matched controls [45]. Similarly, no role of
TLR4 polymorphisms in vaginal colonization with Candida
spp. has been observed [58].
Studies dedicated to identifying common genetic variants
that predispose to bloodstreamCandida infections have revealed
a significant role for non-synonymous polymorphisms in TLR1
[45]. TheseTLR1polymorphisms result in loss-of-functionof the
receptor, defective pattern recognition of the pathogens, and
decreased cytokine production. Another potential mechanism
through which TLR1 could exert its effect was discovered
through the recent finding that b-defensin-3 activates immune
cells through TLR1/TLR2, with an important lytic activity
against C. albicans [59,60]. This is supported by the observation
that polymorphisms in b-defensin-1 are associated with recur-
rent vulvovaginal candidiasis (RVVC) [54]. In the same cohort
of patients with candidemia, persistence of fungemia was
shown to be associated with promoter polymorphisms in the
cytokine genes IL-12B and IL-10 [47]. These polymorphisms
Table 1. Common genetic variants associated with increased susceptibility to Candida infections. MBL, mannose binding lectin.
affected
gene polymorphism type of infection immune defects references
dectin-1 Y238X recurrent vulvovaginal infections and oral/
gastrointestinal colonization
lack of b-glucan recognition, lower
production of TNFa, IL-6 and IL-17
[23]
I223S oropharyngeal candidiasis reduced zymosan-binding capacity and IFN-
g production
[44]
TLR1 R80T
N248S
S602I
candidemia impaired production of cytokines [45]
TLR3 L412F CMC defective TLR3 signalling [46]
IL-12B 22724INS/DEL persistent candidemia lower production of IFN-g [47]
IL-10 21082A/G persistent candidemia higher production of IL-10 [47]
MBL2 codon 54 and 57 candidemia, abdominal Candida infection,
recurrent vulvovaginal candidiasis
lower MBL serum levels [48–50]
IL-4 2589T/C recurrent vulvovaginal candidiasis increased levels of vaginal IL-4 and
reduced levels of nitric oxide and MBL
[51]
21098T/G
2589C/T
233C/T
chronic disseminated candidiasis unknown [52]
NLRP3 length
polymorphism
recurrent vulvovaginal candidiasis impaired production of IL-1b [53]
DEFB1 244C/G C. albicans carriage unknown [54]
CD58.
TAGAP
various SNPs in the
locus
candidemia decreased phagocytosis and cytokine
production
[55]
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IL-12 production capacity of innate immune cells [61–65]. The
persistence of infection was demonstrated to correlate with
decreased IL-12 and increased IL-10 production induced by
the presence of Candida, which may result in inhibition of the
TH1 response that is known to be crucial for anti-Candida sys-
temic immunity [66,67]. In agreement with this, a decreased
production of TH2 cytokines such as IL-4 owing to genetic
variation in the IL4 gene also leads to protective effects [68,69].
Multiple studies have been dedicated to investigate the
role of mannose binding lectin (MBL) deficiency in infections
with Candida spp., because it was demonstrated that MBL
could bind and opsonize fungi to facilitate complement acti-
vation and phagocytosis [69,70]. Indeed, genetic associations
of MBL deficiency with infection risk have been observed in
cohorts of patients with candidemia, abdominal infections
and RVVC [48–50,68].
Candida spp. also cause frequent mucosal infections that
can be an important cause of morbidity [2]. Oropharyngeal
candidiasis (OPC), a mucosal colonization of the mouth
and upper digestive tract, is frequently observed in patients
that are infected with HIV. About 50–95% of patients suffer
this type of candidiasis at least once during their progression
to AIDS [71–73]. A recent study assessed the potential role of
genetic variants of pattern recognition receptors in suscepti-
bility to OPC in West African HIV patients, and revealed
an I223S genetic variant of dectin-1 that was specific for
African populations [44].The genetic studies on Candida infections described above
are variable in terms of size of patient cohorts and statistical
power. While some of the studies had relatively large cohorts,
with appropriate statistical analysis, others were based on
relatively small numbers of patients and this limited the
robustness of the conclusions. Although some of the reported
genetic associations were supported by functional studies
that provided mechanistic explanations for the increased sus-
ceptibility to infection, the common lack of genetic validation
of these genetic associations underlines the importance
of future studies with appropriate statistical power using
independent cohorts of patients.6. Genomic approaches in fungal infections
In addition to the classical candidate-based approaches
for investigating susceptibility to fungal infections, recent
methodological advances have permitted the initiation of
discovery-based genomic approaches to identify novel genetic
variants that impact on fungal disease. Recently, the first
genome-wide association study (GWAS) on a fungal infection
was published [55], in which the authors analysed and
compared 118 989 single-nucleotide polymorphisms (SNPs)
in patients with candidemia and a large cohort of healthy vol-
unteers. A significant association between candidemia
and SNPs in cluster of differentiation (CD) 58 (odds ratio,
OR ¼ 4.68), late cornified envelope 4A (LCE4A; OR ¼ 4.25)
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Figure 3. Microbiomes and immunology. Direct and indirect influences of the microbiome on the physiology of fungal pathogen growth and the innate immune response
as described in the text. In short, colonization with Candida does not induce the production of cytokines. Upon invasion, Candida activates tissue macrophages to induce
production of chemokines and cytokines. This, in turn, will recruit and activate other immune cells from the bloodstream, such as monocytes or neutrophils that will ingest
and kill the pathogens. Activations of dendritic cells will also lead to antigen presentation and activation of T-helper responses that, in turn, will aid pathogen elimination.
CCR2, chemokine receptor type 2; CCL2, chemokine (C–C motif ) ligand 2; NK ¼ natural killer cell; ROS, reactive oxygen species.
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OR ¼ 2.96) loci was identified. The combination of two ormore
risk alleles in these two genes resulted in an almost 20-fold
increase in the risk for candidemia [55]. CD58, and adhesion
molecule on antigen-presenting cells, appeared to be involved
in the inhibition of Candida germination, whereas TAGAP was
needed for optimal Candida-induced cytokine production [55].
More studies are needed to validate these findings, to expand
the depth of these genomic approaches to more genetic var-
iants, and to perform GWASs also in other fungal infections.
Such studies may pave the way for future clinical decisions
based on personalized SNP profiling.7. Understanding the impact of microbiome on
the pathophysiology of fungal infections
Recent years havewitnessed a revolution in our understanding
of how the microbiome composition impacts the health status
of the host [74]. The microbiome composition is strongly influ-
enced by diet, and this can influence colonization of mucosaewith fungi (figure 3). For example, a recent study in mice
showed that dietary coconut oil reduced C. albicans coloniz-
ation of the gastrointestinal tract [75]. Candida colonization is
also influenced by quantitative and qualitative aspects of the
microbiome, such as Lactobacilli that inhibit fungal adhesion
and growth by producing H2O2 and bacteriocin-like com-
pounds [76]. Another example through which microbiome
products influence fungal colonization is that of the production
of short-chain fatty acids by Lactobacilli that can also inhibit
fungal growth [77]. Some bacteria such as Pseudomonas
aeruginosa and Enterococcus faecalis can inhibit C. albicans
hypha formation and thereby have the potential to influence
tissue infiltration [78]. Supporting this, in a Caenorhabditis
elegans infection model, E. faecalis in the gut inhibited
C. albicans hyphal morphogenesis [79]. In contrast, C. albicans
can co-aggregate with Streptococci, which may facilitate the
colonization of oral surfaces by the yeast [80].
Themicrobiome composition not only influences the extent
of Candida colonization on human tissues, but it can also
influence the immune response to Candida species [81–83]
(figure 1). Mice treated with the short-chain fatty acid
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fibres by many gut microorganisms, have numerous immune
alterations, including enhanced generation of macrophage
and dendritic cell precursors, increased number of dendritic
cells in the lungs and reduced TH2 effector function [84]. Lacto-
bacilli in the gut use tryptophan as their energy source and
produce indole-3-aldehyde in the process. Indole-3-aldehyde
stimulates the aryl hydrocarbon receptor, which induces IL-
22 production in NKprotein46þNK1.1low cells, which are, in
turn, protective against Candida colonization at mucosal sur-
faces [85]. Thus, bacterial components of the microbiome can
influence immune responses in the gut and in the lung.
The microbiome composition in humans has also been
demonstrated to influence the immune response against
C. albicans. In patients with hyper-IgE syndrome and CMC,
there is an increase in skin colonization with Gram-negative
bacteria (e.g. Acinetobacter), whereas some of the regular skin
microbiome genera (e.g. Corynebacteria) have a much lower
prevalence than in controls. This pathological colonization
with Gram-negative bacteria can, in turn, suppress S. aureus-
and C. albicans-induced cytokine production [86]. The vaginal
microbiome of patients with vulvovaginal candidiasis is highly
variable, and could not be described by any single profile [87].
In terms of abundance, fungi are relatively rare on human skin
[88], and the fungalmicrobiomehasyet tobe researched indetail.
When the normal immune balance is disturbed, e.g. in
immunocompromised hosts, populations of resident skin
fungi can expand [89]. Indeed, antibiotic treatment in mice
causes an altered gut microbiome that coincides with
outgrowth of commensal Candida species in the gut [90]. In
addition, genetic factors contribute to mycobiome compo-
sition. Fr example, in dectin-1 deficient mice, there is an
altered gut mycobiome, which subsequently increases the
susceptibility to experimental colitis [91].
Oral mycobiome analysis revealed that C. albicans was the
most common fungal microorganism in healthy controls and
HIV-infectedparticipants.Candidacolonization isnegatively cor-
related with the abundance of Pichia farinosa—a near relative of
Candida boidinii. Pichia-conditioned medium is a medium in
which the yeast Pichia has been grown and then removed by fil-
tration. Interestingly, Pichia-conditioned medium inhibits
Candida growth and biofilms, and in a murine oral candidiasis
model, Pichia-conditioned medium lowered the infection score,
fungal burden and tongue epithelial damage [92]. This study
provides proof of principle that investigating the relationship
between the bacteriome and mycobiome, or between variouscomponents of the mycobiome, can both provide new insights
into the pathology of a disease and can lead to novel antifungal
approaches [92].8. Conclusion and future prospects
Fungal infections aremoreprevalent andoftenmore serious than
have been appreciated, and investment is required in basic
research and public engagement to address the clinical challenge
they impose. Although new antifungals and better diagnostics
are under development, the impact of currently available tools
and interventions on mortality rates owing to fungal infection
has not changed significantly in recent years. Therefore, efforts
dedicated to understanding and exploiting our knowledge of
the immunology of fungal infections are highly relevant in
addressing the global fungal infection problem.
Recent research has defined the immunopathology of
many fungal diseases. In some cases, pathology is driven by
fungal invasion and virulence,whereas in others, it ismediated
by over-activation of the inflammatory response to the fungus.
Therefore, it is essential to be able to understand the immuno-
pathology of specific fungal disease settings. Significant strides
have been made in understanding how the immune system is
activated and suppressed by fungal infections, and new oppor-
tunities are presenting themselves to be able to manipulate the
immune response using immune agonists or inhibitors of
inflammation. Next-generation sequencing has revolutionized
our understanding of human genes that predispose patients to
specific fungal infections and these have illuminated funda-
mental mechanisms of immune surveillance and recognition.
Increasingly, it has been recognized that the outcome of an
infection is mediated not only by the fungus and the immune
response, but also by the genetic profile of each patient, and
the modulatory influences of the patient’s microbiome
and mycobiome. Embracing these insights presents new
opportunities for the future of vaccine development, adjunct
immunotherapy and personalized approaches to protecting
and treating patients from fungal infections.
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